Early Real-World Outcomes of Intravitreal Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration in France: A Retrospective Study.

@article{fricker2026early,
  title = {{Early Real-World Outcomes of Intravitreal Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration in France: A Retrospective Study.}},
  author = {Jules Fricker and Lucas Sejournet and Jules Prange and Julien Andre and Remy Calvet and Valentin Rougane and Ségolène Gouze and Maxime Oudard and Ambre Ancel and Alexis Kodjikian and Simona Nicoara and Philippe Desmangles and Thibaud Mathis and Laurent Kodjikian},
  journal = {Ophthalmology and therapy},
  year = {2026},
  month = oct,
  doi = {10.1007/s40123-026-01510-1},
  url = {https://europepmc.org/article/MED/42832168},
  note = {CC BY-NC},
}

TY  - JOUR
TI  - Early Real-World Outcomes of Intravitreal Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration in France: A Retrospective Study.
AU  - Jules Fricker
AU  - Lucas Sejournet
AU  - Jules Prange
AU  - Julien Andre
AU  - Remy Calvet
AU  - Valentin Rougane
AU  - Ségolène Gouze
AU  - Maxime Oudard
AU  - Ambre Ancel
AU  - Alexis Kodjikian
AU  - Simona Nicoara
AU  - Philippe Desmangles
AU  - Thibaud Mathis
AU  - Laurent Kodjikian
PY  - 2026
DA  - 2026/10/05
JO  - Ophthalmology and therapy
DO  - 10.1007/s40123-026-01510-1
UR  - https://europepmc.org/article/MED/42832168
AB  - Introduction  The aim of this work is to evaluate the early real-world effectiveness, anatomical outcomes, and safety of intravitreal aflibercept 8 mg in neovascular aged-related macular degeneration (nAMD) eyes.Methods  This retrospective single-center study included consecutive nAMD eyes treated with at least one aflibercept 8-mg injection between January 2025 and January 2026 in France. Primary outcomes were treatment interval extension and macular drying. Secondary outcomes included changes in best-corrected visual acuity (BCVA), central macula thickness (CMT), OCT biomarkers, and safety. Subgroup analyses were performed according to treatment status, responder profile, and prior anti-VEGF generation. In addition, baseline predictive factors associated with treatment interval extension, achievement of an interval ≥ 12 weeks, and dry macular status were evaluated. A sensitivity analysis was performed in eyes with ≥ 6 months of follow-up.Results  A total of 338 eyes from 267 patients were included (82 treatment-naïve and 256 switched eyes), with a mean follow-up duration of 5.5 ± 3.3 months. In switched eyes, the mean treatment interval increased by +1.8 ± 2.4 weeks (p < 0.001), with significant gains in good responders (+ 2.7 weeks), frequent flyers (+ 0.7 weeks), and poor responders (+ 1.8 weeks) (all p < 0.001). Dry macula rates increased from 39.6% to 70.7% (p < 0.001). Among treatment-naïve eyes, 74.4% achieved a dry macula at the last visit and 97.4% at the 4-week interval following induction. In eyes with ≥ 6 months of follow-up, the interval increased by +1.6 weeks and remained significant (p < 0.001). OCT biomarkers significantly decreased during follow-up (p < 0.001), while BCVA remained stable.Conclusions  Early real-world use of aflibercept 8 mg was associated with improved anatomical outcomes and extended treatment intervals in treatment-naïve and previously treated nAMD eyes, while maintaining stable BCVA and a favorable safety profile. These findings support its potential to reduce treatment burden in routine clinical practice.
SN  - 2193-8245
SN  - 2193-6528
ER  -